Chemosensitization of Cancer Cells by KU-0060648, a Dual Inhibitor of DNA-PK and PI-3K

@article{Munck2012ChemosensitizationOC,
  title={Chemosensitization of Cancer Cells by KU-0060648, a Dual Inhibitor of DNA-PK and PI-3K},
  author={Joanne M Munck and Michael A. Batey and Yan Zhao and Helen Jenkins and Caroline J. Richardson and C{\'e}line Cano and Michele Tavecchio and Jody Barbeau and Julia Bardos and Liam Cornell and Roger John Griffin and Keith Allan Menear and Andrew Slade and Pia A. Thommes and Niall M. B. Martin and David Richard Newell and Graeme C M Smith and Nicola J. Curtin},
  journal={Molecular Cancer Therapeutics},
  year={2012},
  volume={11},
  pages={1789 - 1798}
}
DNA double-strand breaks (DSB) are the most cytotoxic lesions induced by topoisomerase II poisons. Nonhomologous end joining (NHEJ) is a major pathway for DSB repair and requires DNA-dependent protein kinase (DNA-PK) activity. DNA-PK catalytic subunit (DNA-PKcs) is structurally similar to PI-3K, which promotes cell survival and proliferation and is upregulated in many cancers. KU-0060648 is a dual inhibitor of DNA-PK and PI-3K in vitro. KU-0060648 was investigated in a panel of human breast and… Expand
Pharmacologic Inhibitor of DNA-PK, M3814, Potentiates Radiotherapy and Regresses Human Tumors in Mouse Models
TLDR
Oral administration of M3814 to two xenograft models of human cancer, using a clinically established 6-week fractionated radiation schedule, strongly potentiated the antitumor activity of IR and led to complete tumor regression at nontoxic doses, strongly support DNA-PK inhibition as a novel approach for the combination radiotherapy of cancer. Expand
DNA-PK inhibitor peposertib enhances p53-dependent cytotoxicity of DNA double-strand break inducing therapy in acute leukemia
TLDR
Combined with the fixed-ratio liposomal formulation of daunorubicin and cytarabine, CPX-351, M3814 enhanced the efficacy against leukemia cells in vitro and in vivo without increasing hematopoietic toxicity, suggesting that DNA-PK inhibition could offer a novel clinical strategy for harnessing the anticancer potential of p53 in AML therapy. Expand
Therapeutic Implications of p53 Status on Cancer Cell Fate Following Exposure to Ionizing Radiation and the DNA-PK Inhibitor M3814
TLDR
The results identify p53 as a possible biomarker for response of cancer cells to combination treatment with radiation and a DNA-PK inhibitor and suggest that p53 mutation status should be considered in the design of future clinical trials. Expand
AZD7648 is a potent and selective DNA-PK inhibitor that enhances radiation, chemotherapy and olaparib activity
TLDR
The authors show that the DNA-PK inhibitor AZD7648 enhances the activity of radiotherapy, chemotherapy and the PARP inhibitor olaparib in multiple mouse tumour models, enabling sustained tumour regression and providing a clear rationale for its clinical investigation. Expand
Modulation of the DNA-Damage Response by Inhibitors of the Phosphatidylinositol 3-Kinase Related Kinase (PIKK) Family
TLDR
Loss of DNA-PK or ATM activity results in an increased sensitivity to ionising radiation and certain chemotherapeutic agents that elicit DNA DSBs, and these kinases represent attractive targets for the development of radio- and chemo-sensitising agents. Expand
Radiosensitizing activity of a novel Benzoxazine through the promotion of apoptosis and inhibition of DNA repair
TLDR
A novel benzoxazine, 8-methyl-2-(morpholine-4yl)-7-(pyridine-3-methoxy)-4H-1,3-benzoxacine-4-one (LTU27) is presented and its ability to cause sensitization of lung cancer and colon cancer cells to radiation is analyzed. Expand
KU-0060648 inhibits hepatocellular carcinoma cells through DNA-PKcs-dependent and DNA-PKcs-independent mechanisms
TLDR
KU-0060648 inhibits HCC cells through DNA-PKcs-dependent and -independent mechanisms, and miRNA-101, an anti-DNA- PKcs miRNA, was downregulated in human HCC tissues. Expand
Sensitizing Ewing sarcoma to chemo- and radiotherapy by inhibition of the DNA-repair enzymes DNA protein kinase (DNA-PK) and poly-ADP-ribose polymerase (PARP) 1/2
TLDR
Single agent rucaparib ES sensitivity in vitro was not replicated in vivo, and DNA-PK and PARP inhibitors are good chemo-/radiosensitizers in ES. Expand
Identification of DNA-PKcs as a primary resistance factor of salinomycin in osteosarcoma cells
TLDR
This work characterized DNA-dependent protein kinase catalytic subunit (DNA-PKcs) as a primary salinomycin resistance factor in OS cells, and suggested that DNA- PKcs could be a primary resistance factor of sal inomycin inOS cells. Expand
Inhibition of the DNA-Dependent Protein Kinase for Cancer Therapy
TLDR
This review examines the structures of known reversible and irreversible inhibitors, including those based upon chromen-4-one, arylmorpholine, and benzaldehyde scaffolds, to help advance understanding of whether this approach represents a promising therapeutic strategy for the treatment of cancer. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 55 REFERENCES
Preclinical evaluation of a potent novel DNA-dependent protein kinase inhibitor NU7441.
TLDR
NU7441 shows sufficient proof of principle through in vitro and in vivo chemos Sensitization and radiosensitization to justify further development of DNA-PK inhibitors for clinical use. Expand
Radiosensitization and DNA repair inhibition by the combined use of novel inhibitors of DNA-dependent protein kinase and poly(ADP-ribose) polymerase-1.
TLDR
There was a correlation between the ability of the inhibitors to prevent IR-induced DNA DSB repair and their ability to potentiate cytotoxicity and the DNA-PK and PARP-1 inhibitors show potential as tools for anticancer therapeutic intervention. Expand
A novel DNA-dependent protein kinase inhibitor, NU7026, potentiates the cytotoxicity of topoisomerase II poisons used in the treatment of leukemia.
TLDR
The use of a selective small-molecule inhibitor of DNA repair to potentiate topoisomerase II (topo II) poisons is reported for the first time, identifying DNA-dependent protein kinase (DNA-PK) as a potential target for leukemia therapy. Expand
Radiosensitization of human tumor cells by the phosphatidylinositol3-kinase inhibitors wortmannin and LY294002 correlates with inhibition of DNA-dependent protein kinase and prolonged G2-M delay.
TLDR
Inhibition of cellular DNA-PK activity occurred at the same concentrations of wortmannin that caused radiosensitization, and this correlation was found in a range of tumor cell lines, suggesting a new class of radiosensitizers that inhibit the repair of DNA damage. Expand
DNA double-strand break repair pathways and cellular tolerance to inhibitors of topoisomerase II.
TLDR
The results suggest that the xrs repair pathway is required for efficient removal of potentially cytotoxic DSBs that arise in cells treated with topoisomerase II inhibitors. Expand
Increased expression of DNA-dependent protein kinase confers resistance to adriamycin.
TLDR
The overexpression of DNA-PK is shown to be a novel cellular adaptation mechanistically contributing to the resistance of cancer cells to the anthracycline drug adriamycin, and as such, may have implications for its therapeutic use. Expand
DNA-dependent protein kinase in leukaemia cells and correlation with drug sensitivity.
TLDR
The results indicate that DNA-PK is not only involved in the recognition of DNA double-strand breaks (DSB), but also other DNA lesions. Expand
The DNA-dependent protein kinase.
TLDR
Studies on DNA-PK should provide a better understanding of degenerative diseases and cancer, and may lead to improved therapies for these conditions, as well as related proteins involved in DNA damage detection. Expand
Cell Cycle Dependence of DNA-dependent Protein Kinase Phosphorylation in Response to DNA Double Strand Breaks*
TLDR
Results indicate that although IR-induced DNA- PKcs phosphorylation is attenuated in the S phase, DNA-PKcs is preferentially activated by the physiologically relevant DNA replication-associated DSBs at the sites of DNA synthesis. Expand
DNA repair rate and etoposide (VP16) resistance of tumor cell subpopulations derived from a single human small cell lung cancer.
TLDR
It is suggested, that different DSB repair rates among tumor cell subpopulations of individual SCLC tumors may be a major determinant for the variation in clinical treatment effect observed in human SclC tumors of identical histological subtype. Expand
...
1
2
3
4
5
...